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ABSTRACT
In order to evaluate the infectious agents associated with the first episode of severe acute wheezing in
otherwise healthy infants and to define the role of each of them in recurrences, 85 patients in Italy, aged
<12 months, hospitalized because of a first acute episode of wheezing, were prospectively enrolled
between 1 October 2005 and 31 March 2006. Upon enrolment, nasopharyngeal swabs were collected for
the real-time PCR detection of respiratory syncytial virus (RSV) types A and B, influenza virus
types A and B, adenovirus, parainfluenza viruses types 1, 2, 3 and 4, rhinovirus, human metapneumo-
virus, human coronavirus types 229E, OC43, NL63, and HKU1, bocavirus, enterovirus, and paraecho-
virus; nasopharyngeal aspirates were also obtained to detect atypical bacteria. At least one infectious
agent was identified in 76 children (89.4%). RSV was the most frequently detected pathogen and its
prevalence was significantly higher than that of the other pathogens in both age groups, and significantly
higher in the children aged 3–12 months than in those aged <3 months. Only the children with RSV
infection experienced recurrent wheezing. Viral load was significantly higher in children with than in
those without recurrent wheezing. This study shows that RSV is the main reason for hospitalization
during the first wheezing episode in infants, and that it appears to be the only pathogen associated with a
high frequency of recurrences. A high viral load seems to be strictly related to the likelihood of recurrence.
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INTRODUCTION
Wheezing episodes are a common reason for the
hospitalization of infants and young children and
can cause significant clinical and socio-economic
problems [1–4]. Respiratory syncytial virus (RSV)
has long been considered to be the main pathogen
associated with wheezing, and it has been dem-
onstrated that a lower airway illness caused
by RSV in early childhood is an independent
risk-factor for the development of subsequent
wheezing episodes up to adolescence [5,6].
However, recently introduced, simple and
more sensitive diagnostic techniques capable of
identifying infectious agents in respiratory secre-
tions have shown that a number of other patho-
gens can be detected in children with wheezing
[7–11]. Of these, the most frequently found are
viruses such as rhinoviruses, influenza viruses,
human metapneumovirus (hMPV), human
coronaviruses (hCoVs), and human bocavirus,
and some atypical bacteria such as Mycoplasma
pneumoniae and Chlamydophila pneumoniae [12–24].
The importance of each of these infectious
agents as a cause of wheezing has not yet been
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precisely defined, because the studies carried out
so far have not considered all of the pathogens
together or have frequently led to opposite con-
clusions. In particular, it is still not clear which
pathogens are really responsible for severe wheez-
ing that requires hospitalization or are important
in predisposing children to the subsequent
development of recurrent wheezing and asthma.
Defining the role of pathogens more precisely
seems to be particularly important in the case of
children aged <1 year, because acute wheezing in
early life often requires hospitalization, and the
risk that early infection can be associated with a
greater risk of further episodes seems to have
been demonstrated in experimental models and
has also been suggested in human studies [25–27].
The aim of this study was to evaluate the
infectious agents associated with the first episode
of acute wheezing that required the hospitaliza-
tion of otherwise healthy infants during their first
year of life, and to define the role of each in
causing recurrences.
PATIENTS AND METHODS
Study design
This prospective study was carried out between 1 October 2005
and 31 March 2006, at the Institute of Paediatrics, University of
Milan, Italy, and three associated hospitals (Legnano, Pavia
and Imola). The study protocol was approved by the Institu-
tional Review Boards of the four hospitals, and the written
informed consent of a parent or legal guardian was obtained
before the infants were enrolled.
Study population
The study involved otherwise healthy infants aged less than
12 months who were hospitalized in one of the participating
hospitals because of a first acute episode of wheezing during
the study period. The exclusion criteria were premature birth
and the presence of a chronic disease increasing the risk of
complications of a respiratory infection, including chronic
disorders of the pulmonary or cardiovascular system, chronic
metabolic diseases, neoplasias, kidney or liver dysfunction,
haemoglobinopathies, immunosuppression, and genetic or
neurological disorders. There was no refusal to participate.
Upon admission, the demographic characteristics and
medical history of the children were systematically recorded,
using standardized written questionnaires and, after a com-
plete physical examination, children with a diagnosis of
infectious wheezing, based on well-established criteria [28],
were enrolled. The severity of the wheezing was defined on
the basis of a global evaluation of the signs and symptoms. In
particular, wheezing was considered to be severe in the
presence of tachypnoea (‡60 breaths ⁄min), tachycardia
(‡180 beats ⁄min), nasal flaring, retractions, a prolonged expi-
ratory phase, pulse oximetry <92%, and dehydration
(a reduction in body weight of >7%). All of the patients
underwent chest radiography, and pneumonia was defined on
the basis of the presence of a reticulo-nodular infiltrate,
segmental or lobar consolidation, or bilateral consolidations
[29]. Upon enrolment, Virocult (Medical Wire and Equipment,
Corsham, UK) nasopharyngeal swabs were used to collect
specimens for the detection of viruses, and nasopharyngeal
aspirates were obtained for the detection of atypical bacteria.
Acute serum samples were also obtained in order to assay
antibodies to M. pneumoniae and C. pneumoniae.
During their hospital stay, the children’s clinical signs and
symptoms were monitored daily. They were treated with
oxygen when saturation was <92%, and received broncho-
dilators, steroids, antibiotics and ⁄ or intravenous fluids, and
chest physiotherapy as judged necessary by the attending
paediatricians. They were discharged when they were able to
maintain oximetry >95% without oxygen, but their parents
were asked to bring them immediately to the study centre if
there were any recurrent or worsening signs and symptoms.
The medical history, general physical condition and clinical
symptoms of each patient were re-evaluated by investigators
blinded to the aetiological findings 4–6 weeks and 3–6 months
after enrolment, when the children’s histories of wheezing and
respiratory tract infections were carefully assessed. At the first
of these visits, a second serum sample was obtained in order to
assay M. pneumoniae and C. pneumoniae titres during the
convalescent phase.
Identification of viral infections
The Virocult nasopharyngeal swabs were tested by means of
previously described real-time PCR for RSV types A and B
[19,29], influenza virus types A and B [19,29,30], adenovirus
[31], parainfluenza virus types 1, 2, 3 and 4 [32,33], rhino-
virus [32,33], hMPV [19,34–36], hCoV types 229E, OC43,
NL63, and HKU1 genotype A [21,22,37,38], bocavirus [23,39],
enterovirus [11,40,41] and paraechovirus [11,40,41] at the
Department of Virology, Erasmus Medical Centre, Rotter-
dam, The Netherlands. Total nucleic acids were routinely
isolated at the MagnaPureLC Isolation Station (Roche
Applied Science, Penzberg, Germany). A universal internal
control virus was used to monitor the whole process from
nucleic acid isolation until real-time detection. The in-house
real-time PCR for all of the tested viruses and the internal
control phocine distemper virus was designed using Primer
Express software (Applied Biosystem, Nieuwerkerk a ⁄d Ijssel,
The Netherlands).
RNA was amplified in a single-tube, two-step reaction
using the Taqman reverse transcriptase reagents kit and PCR
core reagent kit (Applied Biosystems) on an ABI 7700 or ABI
7500 sequence detection system (Applied Biosystems). As
positive control for each assay, a cultured control virus was
used, except in the case of HKU1 genotype A, for which a
construct was synthesized on the basis of published sequences
containing part of the nucleoprotein gene, and cloned. On the
basis of proficiency testing data, the sensitivity of each assay
was estimated to be less than 500–1000 copies ⁄mL.
Identification of atypical bacterial infections
The nasopharyngeal aspirates were evaluated for the presence
of M. pneumoniae DNA [7,17,42,43] and C. pneumoniae DNA
[7,17,43,44], using a validated nested PCR for both pathogens
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as previously described. Each assay included positive and
negative controls. The MP-1 and MP-2 primer set was used for
M. pneumoniae-specific amplification, followed by the MUH-1
and MUH-2 primers for M. pneumoniae nested PCR
[7,17,42,43]. Touchdown nested PCR for the detection of
C. pneumoniae DNA was performed using primers designed
to detect the major protein of the outer-membrane [7,17,43,44].
Each serum sample was tested for IgM and IgG antibodies
to M. pneumoniae (ELISA; Pantec, Italy) [7,13,17,43], and IgM
and IgG antibodies to C. pneumoniae (microimmunofluores-
cence; Labsystems, Finland) [7,17,43,45], as previously
described.
Acute M. pneumoniae and ⁄or C. pneumoniae infection was
diagnosed if the child showed a significant antibody response
to one of the pathogens in paired sera (for M. pneumoniae, an
IgM-specific titer of ‡1:100 or a four-fold increase in IgG
antibody; for C. pneumoniae, an IgM-specific titer of ‡1:16 or a
four-fold increase in IgG antibody) and ⁄ or if the nasopharyn-
geal aspirates were PCR-positive according to previously
established criteria [7,13,17,43].
Statistical analysis
The data were analyzed using SAS Windows v.12 (SAS
Institute, Cary, NC, USA); a p value of <0.05 was considered
to be statistically significant. Comparisons were made between
infants aged <3 months and those aged 3–12 months. Para-
metric data were evaluated by means of analysis of variance
(ANOVA); abnormally distributed or non-parametric data
were analyzed using the Kruskal–Wallis test. The categorical
data were analyzed by means of contingency analysis and the
chi-squared or Fisher’s test.
RESULTS
The study enrolled 85 infants aged less than
12 months who were hospitalized because of a
first acute episode of wheezing (57 males; mean
age ± standard deviation, 2.95 ± 2.21 months).
Fifty-three patients (62.3%) were aged less than
3 months, and 32 (37.7%) were aged 3–12 months.
All were full-term newborns (61.2% born by means
of an eutocic delivery) and all had a physiological
neonatal history. Twenty-two (25.9%) had a family
history of asthma, all lived in an urban area, and
none had attended a day-care centre before enrol-
ment. There were no differences in the demo-
graphic characteristics of the two age groups.
Table 1 shows the infectious agents detected in
the study population. At least one agent was
identified in 76 of the 85 children (89.4%). Sixty-
one patients (71.8%) were infected with a single
pathogen; 15 were co-infected with different
viruses (17.6%; p <0.0001 vs. patients infected with
a single pathogen); and no pathogen was detected
in nine cases (10.6%; p <0.0001 vs. patients infected
with a single pathogen). There were no significant
differences in the prevalence of the single infec-
tions, co-infections or absence of pathogen in the
two age groups.
RSV was the most frequently detected patho-
gen and its prevalence was significantly higher
than that of the other pathogens in both age
groups, and significantly higher in the children
aged 3–12 months than in those aged <3 months.
With the exception of the children with RSV
co-infections, all of the other viruses were found
only in the youngest age group, whereas
M. pneumoniae was found in a 9-month-old child.
Among the patients infected with a single
pathogen, the RSV cases were due to RSV A in
13 infants (25.0%) and RSV B in 39 (75.0%), the
influenza cases were due to influenza A virus in
two infants (66.7%) and influenza B virus in one
(33.3%), and the hCoV cases were due to hCoV
OC43 in two infants (66.7%) and hCoV HKU1
genotype A in one (33.3%). No single infection
due to adenovirus, rhinovirus, parainfluenza
viruses (types 1, 2, 3 and 4), hCoV 229E and
hCoV NL63, enterovirus or paraechovirus was
observed; these viruses were only detected in
infants with co-infections. C. pneumoniae was
never detected.
Table 1. Infectious agents detected in otherwise healthy
infants hospitalized for a first episode of wheezing
Infections
Age
<3 months
(n = 53)
3–12 months
(n = 32)
Patients infected with a single
pathogen, no. (%)
38 (71.8)a 23 (71.8)
RSV, no. (%) 30 (56.6)b,c 22 (68.7)c
Influenza viruses, no. (%) 3 (5.7) 0 (0.0)
hCoVs, no. (%) 3 (5.7) 0 (0.0)
hMPV, no. (%) 1 (1.9) 0 (0.0)
Bocavirus, no. (%) 1 (1.9) 0 (0.0)
Mycoplasma pneumoniae, no. (%) 0 (0.0) 1 (3.1)
Patients infected with more than
one pathogen, no. (%)
8 (15.1) 7 (21.9)
RSV + hCoVs, no. (%) 2 (3.7) 1 (3.1)
RSV + adenovirus, no. (%) 0 (0.0) 2 (6.3)
RSV + paraechovirus, no. (%) 0 (0.0) 2 (6.3)
RSV + influenza viruses, no. (%) 1 (1.9) 1 (3.1)
RSV + rhinovirus, no. (%) 1 (1.9) 1 (3.1)
Rhinovirus + enterovirus, no. (%) 1 (1.9) 0 (0.0)
Rhinovirus + parainfluenza virus, no. (%) 1 (1.9) 0 (0.0)
Influenza + adenovirus, no. (%) 1 (1.9) 0 (0.0)
Influenza + bocavirus, no. (%) 1 (1.9) 0 (0.0)
Patients not infected with any of the
studied pathogens, no. (%)
7 (13.2) 2 (6.2)
RSV, respiratory syncytial virus; hCoVs, human coronaviruses; hMPV, human
metapneumovirus.
ap <0.0001 vs. patients infected with more than one pathogen and vs. patients not
infected with any of the studied pathogens.
bp <0.05 vs. RSV in infants aged 3–12 months.
cp <0.0001 vs. patients infected with a single pathogen other than RSV.
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Tables 2 and 3 show the clinical presentations
and outcomes, respectively, of the infants infected
with a single pathogen. The onset of the first
wheezing episode was gradual in most of the
children, and not all of them presented with fever.
All were hospitalized because of severe symp-
toms; chest examination showed that all had a
prolonged expiratory phase with wheezes, and
some had a chest radiograph showing signs of
pneumonia.
During the acute episode of wheezing, all of the
patients were treated with bronchodilators, many
received antibiotics, and a minority received
steroids. Most of the RSV and hCoV cases
required intravenous fluids, but supplemental
oxygen was administered to only some of them.
Chest physiotherapy was required because of
atelectasis in a small number of patients with RSV
infection. The duration of hospitalization varied
from 1 to 8 days.
There were no significant differences in clinical
presentation, drug administration or duration of
hospitalization between the patients, with respect
to pathogen, or between the two age groups.
However, after the initial episode of wheezing
that led to enrolment, only infants with RSV
infection experienced at least one further episode
in the following 6 months.
Table 4 summarizes the relationships between
RSV and the clinical data. Clinical presentations
and outcomes were similar regardless of the type
of RSV. However, although viral load did not
correlate with the severity of disease, the numbers
of RSV copies ⁄mL were significantly higher in the
children with recurrent wheezing than in those
without.
Table 2. Clinical presentation of infants infected with a single pathogen
Characteristic
Age
<3 months 3–12 months
RSV (n = 30) Influenza (n = 3) hCoVs (n = 3) hMPV (n = 1) Bocavirus (n = 1) RSV (n = 22)
Mycoplasma
pneumoniae (n = 1)
Onset, no. (%)
Gradual 25 (83.3) 2 (66.7) 2 (66.7) 0 (0.0) 0 (0.0) 14 (63.6) 1 (100.0)
Acute 5 (16.7) 1 (33.3) 1 (33.3) 1 (100.0) 1 (100.0) 8 (36.4) 0 (0.0)
Rectal temperature ‡38C, no. (%) 9 (30.0) 2 (66.7) 1 (33.3) 0 (0.0) 1 (100.0) 9 (40.9) 1 (100.0)
Severe symptoms, no. (%)
Tachypnoea ‡60 breaths ⁄min 20 (66.7) 1 (33.3) 3 (100.0) 0 (0.0) 1 (100.0) 10 (45.5) 0 (0.0)
Tachycardia ‡180 beats ⁄min 11 (36.7) 0 (0.0) 1 (33.3) 0 (0.0) 0 (0.0) 6 (27.3) 0 (0.0)
Nasal flaring 23 (76.7) 1 (33.3) 3 (100.0) 0 (0.0) 1 (100.0) 15 (68.2) 1 (100.0)
Prolonged expiratory
phase with wheezes
30 (100.0) 3 (100.0) 3 (100.0) 1 (100.0) 1 (100.0) 22 (100.0) 1 (100.0)
Pulse oximetry <92% 10 (33.3) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 2 (9.1) 0 (0.0)
Dehydration 20 (66.7) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 11 (50.0) 0 (0.0)
X-ray with evidence of
pneumonia, no. (%)
17 (56.7) 1 (33.3) 1 (33.3) 0 (0.0) 1 (100.0) 8 (36.4) 1 (100.0)
RSV, respiratory syncytial virus; hCoVs, human coronaviruses; hMPV, human metapneumovirus. There were no significant differences between the pathogens or age groups.
Table 3. Outcome of infants infected with a single pathogen.
Variable
Age
<3 months 3–12 months
RSV (n = 30) Influenza (n = 3) hCoVs (n = 3) hMPV (n = 1) Bocavirus (n = 1) RSV (n = 22)
Mycoplasma
pneumoniae (n = 1)
Treatment, no. (%)
Bronchodilators 30 (100.0) 3 (100.0) 3 (100.0) 1 (100.0) 1 (100.0) 22 (100.0) 1 (100.0)
Steroids 8 (26.7) 1 (33.3) 0 (0.0) 0 (0.0) 1 (100.0) 8 (36.4) 0 (0.0)
Antibiotics 16 (53.3) 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 7 (31.8) 1 (100.0)
Intravenous fluids 20 (66.7) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 11 (50.0) 0 (0.0)
Supplemental oxygen 10 (33.3) 0 (0.0) 2 (66.7) 0 (0.0) 0 (0.0) 2 (9.1) 0 (0.0)
Chest physiotherapy 3 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (9.1) 0 (0.0)
Duration of hospitalization,
mean days ± SD
5.96 (2.43) 5.0 (1.0) 5.33 (1.15) 4.0 5.0 5.47 (2.15) 6.0
Recurrent wheezing in the following 6 months, no. (%)
At least one episode 18 (60.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 14 (63.6) 0 (0.0)
More than one episode 3 (10.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (13.6) 0 (0.0)
RSV, respiratory syncytial virus; hCoVs, human coronaviruses; hMPV, human metapneumovirus. There were no significant differences between the pathogens or age groups.
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DISCUSSION
Our findings indicate that RSV is the main
pathogen associated with the first episode of
wheezing requiring hospitalization in infants
younger than 1 year, and that the other respira-
tory pathogens recently suggested to play a
significant pathogenic role [7,8,10–24] are only
marginally important at this stage. More than
60% of the infants in our study sample were
infected with RSV, whereas the prevalence of the
other pathogens never exceeded 6%. The absolute
relevance of RSV was particularly evident among
the 23 infants aged 3–12 months infected with a
single pathogen, 22 of whom (95.7%) had RSV
infection. However, even in the first 3 months of
life, an association between wheezing and respi-
ratory infections due to pathogens other than RSV
was uncommon, occurring in only eight (21.1%)
of the 38 children in whom a single pathogen was
detected. The importance of RSV in the infants’
first wheezing episode was also clear in the
co-infected cases, because 11 of the 15 cases in
whom more than one pathogen was detected
(73.3%) had RSV infection.
The study was carried out during the late
autumn and winter periods, when RSV and
influenza viruses are often associated with epi-
demic attacks [18,19,46], which may be a limita-
tion, as it has been found that some other
respiratory pathogens (including recently identi-
fied viruses and atypical bacteria) [10–24] can be
isolated in children throughout the year. It is
therefore possible that, if the study had extended
over a longer period, the proportions of wheezing
episodes associated with the different infectious
pathogens may have been slightly different.
However, as most cases of wheezing in the first
year of life occur during late autumn and winter
[1–4], it is unlikely that these differences would
significantly change the outcome of the current
study.
Our knowledge of the real importance of
different respiratory pathogens in causing wheez-
ing in the first year of life is relatively poor
because most of the published studies of infec-
tious wheezing in children considered only a
single pathogen and ⁄ or did not consider the
subjects aged less than 1 year as a separate group.
In addition, most of the papers do not specify
whether the studied wheezing episode was the
first, and, in some cases, the disease for which
each child was admitted is not precisely defined.
However, the results of the few studies compar-
ing different infectious agents (but not atypical
bacteria) and their association with wheezing in
early life have also highlighted the primary role of
RSV [9,11,14,15].
The clinical relevance of wheezing episodes
does not seem to depend on the associated
infectious agent. Although only a small number
of children in the current study had infections due
to a pathogen other than RSV, all of the data
regarding the onset and severity of the disease,
drug administration and duration of hospitaliza-
tion are similar regardless of aetiology. These
findings suggest that all of the respiratory patho-
gens can cause wheezing, and that all of them
lead to a similar clinical presentation in hospita-
lized infants. However, this does not mean that
the clinical impact of the studied pathogens was
similar, because it is possible that respiratory
pathogens other than RSV may cause more
frequent, although less severe, wheezing in
children not requiring hospitalization.
Recurrences were observed only in patients
infected with RSV. The finding that RSV remains
the most important pathogen associated with the
first episode of wheezing during the first year of
life, and that only subjects infected with this virus
are at risk of developing long-term airway hyper-
responsiveness, confirm the data suggesting that
Table 4. Relationship between respiratory syncytial virus
(RSV) and clinical data in children with RSV infection
Characteristic
RSV viral load
(copies ⁄mL)
RSV A
(n = 13)
RSV B
(n = 39)
Rectal temperature
‡38C (5.50 · 105) ± (2.01 · 106) 3 (25.0) 11 (28.2)
<38C (4.20 · 105) ± (7.89 · 105) 10 (75.0) 28 (71.8)
Severe symptoms
Tachypnoea ‡60
breaths ⁄min
(3.53 · 105) ± (8.17 · 105) 8 (61.5) 22 (56.4)
Breath rate <60
breaths ⁄min
(6.59 · 105) ± (2.39 · 106) 5 (38.5) 17 (43.6)
Pulse oximetry <92% (7.06 · 105) ± (1.42 · 106) 3 (23.1) 9 (23.1)
Pulse oximetry ‡92% (4.75 · 105) ± (1.74 · 106) 10 (76.9) 30 (76.9)
X-ray
Evidence of pneumonia (6.03 · 105) ± (1.79 · 106) 6 (46.2) 19 (48.7)
No evidence of pneumonia (5.40 · 105) ± (2.10 · 106) 7 (53.8) 20 (51.3)
Drug administration
Antibiotics (5.49 · 105) ± (3.10 · 106) 5 (38.5) 18 (46.2)
No antibiotics (5.10 · 105) ± (1.49 · 106) 8 (61.5) 21 (53.8)
Intravenous fluids (4.17 · 105) ± (1.76 · 106) 6 (46.2) 20 (51.3)
No intravenous fluids (5.12 · 105) ± (1.82 · 105) 7 (53.8) 19 (48.7)
Duration of hospitalization
<4 days (6.77 · 105) ± (2.40 · 106) 6 (46.2) 19 (48.7)
‡4 days (4.27 · 105) ± (9.98 · 105) 7 (53.8) 20 (51.3)
Recurrent wheezing in the following 6 months
At least one episode
of wheezing
(8.27 · 105) ± (2.10 · 106)* 8 (61.5) 24 (61.5)
No wheezing (9.88 · 102) ± (2.41 · 103) 5 (38.5) 15 (38.5)
Percentages in parentheses. RSV, respiratory syncytial virus.
*p <0.05 vs. no wheezing.
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RSV induces age-related changes in lung function
[5,25–27]. Mouse studies have shown that the
probability of a chronic alteration in lung function
is greater the earlier the first RSV infection occurs,
as is the probability that a subsequent infection
will be followed by severe wheezing [25,47].
Earlier infection seems to induce a polarized
Th2 response which, in the case of re-infection,
causes exacerbated disease, as indicated by en-
hanced pulmonary resistance, mucus hyper-
production, eosinophilia, and high Th2 cytokine
levels [48–50]. Our data suggest that, in humans,
the period during which RSV infection can lead to
a greater risk of further wheezing episodes
extends at least until the end of the first year of
life. The proportion of children in the current
study infected by RSV who experienced a new
episode of wheezing in the 6 months following
the first episode was virtually the same in both
age groups, whereas none of the children whose
first wheezing episode was associated with an
infectious agent other than RSV experienced a
further episode.
This study also demonstrates for the first time
that RSV viral load predicts the tendency to recur,
but not disease severity, in children hospitalized
because of a first wheezing episode. On the
contrary, the type of RSV does not seem to be
related to the clinical presentation, outcome or
recurrence. Recent studies have assessed the role
of host and viral factors in influencing RSV
illness, but their results are controversial.
A relationship between RSV genotypes and
clinical data has not been completely established
[51–53], and RSV viral load appears to correlate
with disease severity in some studies [54,55] but
not in others [51].
Further studies comparing RSV viral load in
outpatients and hospitalized infants with wheez-
ing, as well as in paediatric patients with different
types of respiratory tract infection, are required to
clarify its role in acute illnesses. However, this is
the first study correlating RSV viral load with the
development of subsequent recurrent wheezing,
which is the primary concern with RSV infections
acquired in early life.
In conclusion, our findings show that RSV is
the main cause of hospitalization during a first
wheezing episode in the first year of life, and that
it is the only pathogen associated with a high
frequency of recurrence. A high RSV viral load
appears to be strictly related to recurrence. These
results suggest that every effort should be made
to prevent RSV infection and to contain RSV
replication in the first year of life to reduce the
risk of subsequent episodes of wheezing.
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